Skip to main content
SpringerLink
Log in

Lung Cancer

  • Chapter
Cancer Chemotherapy by Infusion

Abstract

The well-known resistance of nonoat cell lung carcinomas to conventional forms of chemotherapy has led us, since 1979, to use continuous, prolonged infusions of cytostatic drugs in order to try to overcome the kinetic resistance and to prolong the inhibition of DNA repair without increasing the toxicity. This chapter reports several consecutive phase 2 trials conducted in collaboration with members of the French Thoracic Oncology club.* All were based on a combination of cisplatin and bleomycin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cano JP, Israel L, Catalin J. Clinical pharmacokinetics of Cis-DDP in patients after 5–6 days fractionated administration by infusion (20 mg/m2/day). Communication to 12th Int Cong Chemother. Florence, 1981.

    Google Scholar 

  2. Einhorn LH, Donohue J. Cis-diammino dichloro platinum, vinblastine and bleomycin chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 27: 293–98.

    Google Scholar 

  3. Haas CD, Coltman CA, Gottlieb JA, et al. Phase 2 evaluation of bleomycin. Cancer 1976; 38: 8–12.

    Article  PubMed  CAS  Google Scholar 

  4. Okuyama S, Mishina H. Consecutive therapy of cancer aimed at perpetuation of repairable damage: a hypothesis unifying radiotherapy and chemotherapy. J Clin Hematol Oncol 1980; 10: 83–93.

    Google Scholar 

  5. Einhorn LH, Donohue J. Combination chemotherapy in disseminated testicular cancer. The Indiana University experience. Sem Oncol 1979; 6: 87–93.

    CAS  Google Scholar 

  6. Israel L, Aguilera J, Soudant J, Penot JC, Breau JL, Morere JF. Bleomycin and cisplatinum with or without mitomycin-C in 110 previously untreated patients with head and neck cancer. Am J Clin Oncol 1983; 6: 305–11.

    Article  PubMed  CAS  Google Scholar 

  7. Cooper KR, Hong WK. Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 1981; 65: 419–25.

    PubMed  CAS  Google Scholar 

  8. Sikic B, Collins JM, Mimnaugh EG, Gram TE. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 1978; 62: 2011–17.

    PubMed  CAS  Google Scholar 

  9. Peng YM, Albert DS, Chen HSG, Mason N, Hoon TE. Antitumor activity and plasmakinetics of bleomycin by continuous and intermittent administration. Br J Cancer 1980; 41: 644–51.

    Article  PubMed  CAS  Google Scholar 

  10. Breau JL, Israel L, Pochmalicki G, Spaulding C. Efficacité de la méthylprednisolone dans la prevention des vomissements dus aux chimiothérapies par sels de platine dans un essai randomise. Nouv Presse Méd 1983; 12: 2058.

    CAS  Google Scholar 

  11. Israel L, Breau JL, Baudelot J, et al. Plasma exchange as a means of decreasing bleomycin induced pulmonary toxicity. Bull Cancer (in press).

    Google Scholar 

  12. Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in thrombopenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC Lung Cancer Working Party (Belgium). Cancer 1982; 50: 2751–56.

    Article  PubMed  CAS  Google Scholar 

  13. Pedersen AG, Hansen HH. Etoposide (VP-16) in the treatment of lung cancer. Cancer Treat Rev 1983; 10: 245–54.

    Article  PubMed  CAS  Google Scholar 

  14. Gralla JR, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414–20.

    PubMed  CAS  Google Scholar 

  15. Elliott JA, Ahmedzai S, Stevenson RD, Durward AJ, Caiman KC. Vindesine and cisplatin combination chemotherapy composed with vindesine as a single agent in the management of nonsmall-cell lung cancer: a randomized study. Eur J Clin Oncol 1984; 20: 1025–32.

    Article  CAS  Google Scholar 

  16. Niederle J, Shutte N, Roer N, Seeber S, Schmidt CG (1983). Inoperable large-cell carcinoma of the lung. Treatment with vindesine (VDS) and cisplatin (DDP). Proc AACR (abstr 606) 1983.

    Google Scholar 

  17. Briancon S, Thisse JY, Feintrenie X, Barral D, Lamaze R, Lamy P. Vindesine in stage 3 nonsmall- cell carcinoma of the lung: a randomized trial combination with either cyclophosphamide or cisplatin. Proc 13th Int Cong Chemother, Vienna SE 12.1.15 Part 248 1983; 63–68.

    Google Scholar 

  18. Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC Lung Cancer Working Party (Belgium). Cancer 1982; 50: 2751–56.

    Article  PubMed  CAS  Google Scholar 

  19. Klastersky J, Sculier JP, Nicaise C, et al. Combination chemotherapy with cisplatin, etoposide and vindesine in nonsmall-cell lung carcinoma. A clinical trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 1983; 67: 727–30.

    PubMed  CAS  Google Scholar 

  20. Miller TW. Treatment of advanced nonsmall-cell lung cancer (NSLC) with mitomycin-C plus cisplatin plus vindesine (MiPE): comparisons to other mitomycin-C plus vinca-containing combinations (for the Southwest Oncology Group). Proc. ASCO (Abstr C898) 1984.

    Google Scholar 

  21. Rafkin HS. Etude de la survie des tumeurs bronchiques classées T3 opérées à l’exclusion des carcinomes anaplasiques à petites cellules. Thèse de doctorat en médecine, Université Paris VII. Faculté de médecine Xavier Bichat. Paris: Editions de la Faculté de Médecine Xavier Bichat, 1984.

    Google Scholar 

  22. Livingston RB, Carter SK. Single agents in cancer chemotherapy. New York: Plenum, 1970.

    Google Scholar 

  23. Kish J, Ensley J, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Superior response rate with 96 hour 5-fluorouracil (5-FU) infusion vs 5-FU bolus combined with cis-platinum (CACP) in a randomized trial for recurrent and advanced squamous head and neck cancer. ASCO abstr C695, 1984.

    Google Scholar 

  24. Weiden PL, Einstein AB, Rudolph RH. Cisplatin and 5-FU infusion chemotherapy for nonsmall- cell lung cancer (meeting abstr). Proc Annu Meet Am Soc Clin Oncol 1984; 3: 215.

    Google Scholar 

  25. Trybula M, Taylor SG, Bonomi P, et al. Preoperative simultaneous cisplatin/5-fluorouracil and radiotherapy in clinical stage 3 nonsmall-cell bronchogenic carcinoma. ASCO abstr C873 1984.

    Google Scholar 

  26. Byfield JE, Stanton W, Sharp TR, Frankel SS, Koziol J. Phase 1–2 study of 120-hour infused 5-FU and split-course radiation therapy in localized nonsmall-cell lung cancer. Cancer Treat Rep 1983; 67(10): 933–36.

    PubMed  CAS  Google Scholar 

  27. Matelski HW, Lokich JJ, Huberman MS, et al. Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small-cell lung cancer. Am J Clin Oncol 1984; 729–32.

    Google Scholar 

  28. O’Donnell JF, Maurer LH, Forcier RJ, LeMarbre PA, Quinn BM, Stern R. Intensive cytosine arabinoside therapy in small-cell carcinoma of the lung. Am J Clin Oncol 1984; 7: 415–18.

    Article  PubMed  Google Scholar 

  29. Huberman M, Lokich JJ, Greene R, et al. Vinblastine plus cis-platin in advanced nonsmall-cell lung cancer: lack of advantage for vinblastine infusion schedule. Cancer Treat Rep 1986; 70: 287–89.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Lucien Israel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Luc Breau M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean François Morere M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Precept Press, Inc.

About this chapter

Cite this chapter

Israel, L., Breau, JL., Morere, J.F. (1987). Lung Cancer. In: Cancer Chemotherapy by Infusion. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3193-0_26

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-3193-0_26

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-7932-7

  • Online ISBN: 978-94-009-3193-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation